- Report
- October 2023
- 156 Pages
Global
From €2390EUR$2,500USD£2,054GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1912EUR$2,000USD£1,643GBP
- Drug Pipelines
- April 2024
- 202 Pages
Global
From €7600EUR$7,950USD£6,531GBP
- Report
- January 2022
- 60 Pages
Global
From €3776EUR$3,950USD£3,245GBP
- Report
- August 2022
United States
From €1855EUR$1,940USD£1,594GBP
- Report
- August 2022
Global
From €755EUR$790USD£649GBP
- Report
- February 2021
Global
From €2830EUR$2,960USD£2,432GBP
- Report
- August 2021
Europe
From €3270EUR$3,420USD£2,810GBP
- Report
- August 2021
Global
From €3815EUR$3,990USD£3,278GBP
- Report
- July 2022
- 59 Pages
Global
From €3341EUR$3,495USD£2,871GBP
- Report
- October 2020
- 31 Pages
Global
From €3819EUR$3,995USD£3,282GBP
- Drug Pipelines
- June 2020
- 189 Pages
Global
From €1912EUR$2,000USD£1,643GBP
Sjogren Syndrome is an autoimmune disorder that affects the body's ability to produce tears and saliva. It is characterized by dry eyes and dry mouth, and can lead to other complications such as fatigue, joint pain, and difficulty swallowing. Treatment for Sjogren Syndrome typically involves medications to reduce inflammation, increase saliva production, and improve tear production.
Immune Disorders Drugs are a class of medications used to treat autoimmune disorders such as Sjogren Syndrome. These drugs work by suppressing the immune system, which helps to reduce inflammation and improve symptoms. Common Immune Disorders Drugs used to treat Sjogren Syndrome include corticosteroids, antimalarials, and biologics.
The Sjogren Syndrome Drug market is a subset of the larger Immune Disorders Drugs market. It is composed of companies that specialize in the development and manufacture of medications used to treat Sjogren Syndrome. Some of the companies in the Sjogren Syndrome Drug market include AbbVie, Amgen, AstraZeneca, Biogen, and Novartis. Show Less Read more